Hariyanto performed a meta-analysis on the application of DPP4 inhibitors in COVID-19 patients with T2DM, and the results showed that there was no beneficial outcome compared to patients without DPP4 inhibitor treatment (Hariyanto and Kurniawan, 2021). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.